永赢中证全指医疗器械ETF发起联接C(013416)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
-3,274,857.23 |
-44,296,998.25 |
-55,540,090.80 |
-35,434,223.31 |
| 利息合计 |
9,810.28 |
31,398.19 |
16,773.52 |
52,702.41 |
| 其中：存款利息收入 |
7,974.89 |
31,398.19 |
16,773.52 |
52,702.41 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
1,835.39 |
- |
- |
- |
| 投资收益合计 |
-10,149,581.21 |
-74,949,892.60 |
-23,002,868.49 |
-9,202,697.44 |
| 其中：股票投资收益 |
-41,540.20 |
-971,269.85 |
-185,633.06 |
-662,862.86 |
| 基金投资收益 |
-10,164,313.02 |
-74,194,369.06 |
-22,914,346.53 |
-8,644,528.66 |
| 债券投资收益 |
55,918.47 |
214,599.32 |
96,282.23 |
49,622.03 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
353.54 |
1,146.99 |
828.87 |
55,072.05 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
6,814,757.40 |
30,494,124.31 |
-32,575,624.30 |
-26,375,301.10 |
| 其他收入 |
50,156.30 |
127,371.85 |
21,628.47 |
91,072.82 |
| 费用 |
375,447.08 |
792,058.10 |
382,002.68 |
715,920.27 |
| 管理人报酬 |
28,233.85 |
72,731.53 |
41,548.50 |
96,344.75 |
| 基金托管费 |
5,646.78 |
14,546.25 |
8,309.65 |
19,268.97 |
| 销售服务费 |
200,652.33 |
466,921.17 |
241,939.93 |
420,315.53 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
52,698.89 |
60,826.05 |
2,601.09 |
1,246.14 |
| 其中：卖出回购金融资产支出 |
52,698.89 |
60,826.05 |
2,601.09 |
1,246.14 |
| 其他费用 |
88,215.23 |
177,033.10 |
87,603.51 |
178,744.88 |
| 利润总额 |
-3,650,304.31 |
-45,089,056.35 |
-55,922,093.48 |
-36,150,143.58 |
微信公众号
证券之星APP
基本资料
